Overview

This trial is active, not recruiting.

Condition pancreatic adenocarcinoma
Treatment mln0264
Phase phase 2
Target GCC
Sponsor Millennium Pharmaceuticals, Inc.
Start date July 2014
End date May 2018
Trial size 81 participants
Trial identifier NCT02202785, 2014-000805-11, C26003, REec-2014-1177, U1111-1155-8964

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with advanced or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the pancreas.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs. The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
mln0264
MLN0264 IV infusion

Primary Outcomes

Measure
Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)
time frame: From 21 days, every other cycle, starting with Cycle 2 until disease progression, death or study closure (up to 6 months after the enrollment of the last patient)

Secondary Outcomes

Measure
Number of Participants With Adverse Events (AEs)
time frame: From the first dose through 30 days after the last dose of study medication (Up to 13 months)
Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings
time frame: Day 1 of each 21 day cycle and 30 days after the last dose of study medication (Up to 13 months)
Number of Participants With Potentially Clinically Significant Vital Signs Findings
time frame: Day 1 of each 21 day cycle and 30 days after the last dose of study medication (Up to 13 months)
Progression Free Survival (PFS)
time frame: Day 21 of every other 21-day cycle starting with Cycle 2, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (approximately 18 months)
Duration of Response
time frame: From first documented response until disease progression (Up to 18 months)
Disease Control Rate
time frame: Day 21 of every other 21-day cycle starting with Cycle 2, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (Approximately 18 months)
Overall Survival (OS)
time frame: Until death or 6 months after the last patient completes treatment—whichever occurs first
Cmax: Maximum Observed Serum Concentration for MLN0264
time frame: Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose.
Serum Concentration Conjugated and Unconjugated Total Antibody
time frame: Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose.
Serum Concentration of Monomethyl Auristatin E (MMAE)
time frame: Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose.
Change from Baseline in Tumor Size
time frame: Day 21 of each 21-day cycle, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (Approximately 18 months)
Guanylyl Cyclase C (GCC) H-score assessed by immunohistochemistry (IHC)
time frame: From pre-screening through end of study (approximately 20 months)
Assessment of antitherapeutic antibodies (ATA)
time frame: Pre-dose of each 21 day cycle and 30 days after last dose of study medication (Up to 13 months)

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Male or female participants 18 years of age or older when written informed consent is obtained. 2. Histologically confirmed metastatic or advanced inoperable adenocarcinoma of the pancreas with immunohistochemistry (IHC) evidence of guanylyl cyclase C (GCC) expression indicated by an H-score of 10 or greater. 3. Treatment with 1 or more prior chemotherapies for advanced or metastatic adenocarcinoma of the pancreas. 4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. All scans and x-rays used to document measurable disease must be done within 28 days before enrollment (ascites and bone lesions are not considered measureable disease). 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days before enrollment. 6. Female participants who: - Are postmenopausal for at least 1 year before the screening visit, OR - Are surgically sterile, OR - If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study drug, or - Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.) Male participants, even if surgically sterilized (ie, status postvasectomy), who: - Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or - Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception.) 7. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care. 8. Adequate organ and hematological function as evidenced by the following laboratory values within 14 days before enrollment: - Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L - Platelet count ≥ 100 x 10^9/L - Hemoglobin ≥ 9 g/dL - Activated partial thromboplastin time (aPTT) ≤ 1.5 x the upper limit of the normal range (ULN) per institutional laboratory normal range - International normalized ratio (INR) ≤ 1.5 x ULN - Serum creatinine ≤ 1.5 x ULN - Total bilirubin ≤ 1.5 x ULN - Albumin ≥ 3g/dL - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN - Serum lipase ≤ 3 x ULN and serum amylase within the normal range 9. Resolution of all toxic effects of prior treatments except alopecia to Grade 0 or 1 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. 10. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures. Exclusion Criteria: 1. Radiotherapy within 4 weeks before enrollment. 2. Concurrent treatment or treatment within 4 weeks of study entry with any other investigational agent or chemotherapy. 3. Female participants who are lactating and breastfeeding or have a positive pregnancy test during the Screening period. 4. Uncontrolled, clinically significant, symptomatic cardiovascular disease within 6 months before enrollment, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication. 5. Treatment with any medication that has a clinically relevant potential risk of prolonging the QT interval or inducing torsades de pointes that cannot be discontinued or switched to a different medication before starting study drug. 6. Participants with electrocardiogram (ECG) abnormalities considered by the investigator to be clinically significant, or repeated baseline prolongation of the rate-corrected QT interval (QTc). 7. Ongoing or clinically significant active infection as judged by the investigator. 8. Signs of peripheral neuropathy (PN) ≥ NCI CTCAE Grade 2. 9. Concomitant chemotherapy, hormonal therapy, immunotherapy, or any other form of cancer treatment. 10. Use of strong cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks before the first dose of study drug. 11. Any preexisting medical condition of sufficient severity to prevent full compliance with the study. 12. History of or current neoplasm other than gastric adenocarcinoma, except for curatively treated nonmelanoma skin cancer or in situ carcinoma of the cervix uteri. 13. Known diagnosis of human immunodeficiency virus (HIV) infection (testing is not mandatory). 14. Symptomatic brain metastases. 15. Ongoing anticoagulant therapy (eg, aspirin, coumadin, heparin).

Additional Information

Official title A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)
Description The drug being tested in this study is called MLN0264. MLN0264 is being tested to treat tumors in people who have metastatic adenocarcinoma of the pancreas expressing guanylyl cyclase C (GCC). This study will assess tumor size reduction in patients who are administered MLN0264. The study will enroll 42 to 81 patients. All participants will be administered MLN0264 at 1.8 mg/kg as a single, 30-minute, intravenous (IV) infusion on Day 1 of each 3-week treatment cycle, followed by a rest period of 20 days. Participants will continue to receive MLN0264 for up to 1 year or until disease progression or unacceptable toxicity occurs. This multi-centre trial will be conducted worldwide. The overall time to participate in this study is approximately 19 months. Participants will make 3 to 6 visits to the clinic per treatment cycle, an end-of-treatment visit will occur 30 days after the last dose of study medication, and follow-up assessments will occur every 12 weeks until death or 6 months after the last patient completes treatment - whichever occurs first.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Millennium Pharmaceuticals, Inc..
Location data was received from the National Cancer Institute and was last updated in July 2016.